{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:28:44Z","timestamp":1792895324383,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed to investigate the expression profile of TFE3 in renal cell carcinoma (RCC) and the clinicopathological features as well as prognosis of TFE3-positive RCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Tissue sections from 796 patients with RCC were collected for immunohistochemical staining of TFE3. Molecular TFE3 rearrangement tests were also carried out on the TFE3-positive RCCs using fluorescence <jats:italic>in situ<\/jats:italic> hybridization and RNA-sequencing assays. Both clinicopathological features and follow-up information were collected for further analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The present study showed that 91 patients with RCC (91\/796, 11.4%) were TFE3 positive expression but only 31 (31\/91, 34.1%) of the patients were diagnosed with Xp11.2 translocation RCC. Further, it was found that the patients with TFE3-positive RCCs were more likely to develop lymph node and distant metastasis at diagnosis as well as presented a significantly higher WHO\/ISUP nuclear grade and AJCC stage as compared with patients with TFE3-negative RCCs (<jats:italic>p<\/jats:italic>&amp;lt;0.01). Results of univariate and multivariate analyses showed that TFE3 positive expression was an independent prognostic factor associated with poor progression-free survival. Further, the findings of survival analysis showed that patients with positive TFE3 expression showed a shorter progression-free survival as compared with the patients with negative expression of TFE3 (<jats:italic>p<\/jats:italic>&amp;lt;0.001). In addition, results of the survival analysis found that there was no significant difference in progression-free survival between the Xp11.2 translocation RCC and TFE3-positive non-Xp11.2 translocation RCC groups (<jats:italic>p<\/jats:italic>=0.9607).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study found that nuclear TFE3 expression is not specific to the Xp11.2 translocation RCC. Moreover, the positive TFE3 expression is associated with tumor progression and poor prognosis in patients with RCC irrespective of the presence of TFE3 translocation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1017425","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T04:40:17Z","timestamp":1665031217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiang","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2015.02.003","article-title":"MiT family translocation renal cell carcinoma","volume":"32","author":"Argani","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206899","article-title":"Gene of the month: TFE 3","volume":"73","author":"Pinto","year":"2020","journal-title":"J Clin Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.phrs.2015.04.006","article-title":"The MITF family of transcription factors: Role in endolysosomal biogenesis, wnt signaling, and oncogenesis","volume":"99","author":"Ploper","year":"2015","journal-title":"Pharmacol Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1126\/scisignal.2004754","article-title":"The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris","volume":"7","author":"Martina","year":"2014","journal-title":"Sci Signaling"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01628-8","article-title":"Nuclear translocation of TFE3 under hypoxia enhances the engraftment of human hematopoietic stem cells","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.83","article-title":"Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases","volume":"27","author":"Hodge","year":"2014","journal-title":"Modern Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1309\/ajcpq6llfmc4oxgc","article-title":"Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation incidence, characteristics, and prognosis","volume":"137","author":"Klatte","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers11081110","article-title":"MiT family translocation renal cell carcinoma: From the early descriptions to the current knowledge","volume":"11","author":"Calio","year":"2019","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31824dd972","article-title":"TFE3 rearrangements in adult renal cell carcinoma: Clinical and pathologic features with outcome in a Large series of consecutively treated patients","volume":"36","author":"Sukov","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31824f24a6","article-title":"Translocation renal cell carcinomas in adults: A single-institution experience","volume":"36","author":"Zhong","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/his.13167","article-title":"Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas","volume":"70","author":"Classe","year":"2017","journal-title":"Histopathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/his.13700","article-title":"TFE3 translocation and protein expression in renal cell carcinoma are correlated with poor prognosis","volume":"73","author":"Lee","year":"2018","journal-title":"Histopathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.784993","article-title":"Xp11.2 translocation renal cell carcinoma with TFE3 rearrangement: Distinct morphological features and prognosis with different fusion partners","volume":"11","author":"Ge","year":"2021","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10995","article-title":"Granular cell tumors overexpress TFE3 without gene rearrangement: Evaluation of immunohistochemistry and break-apart FISH in 45 cases","volume":"18","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"key":"B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.humpath.2019.02.008","article-title":"Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: A comparative, 2-laboratory study","volume":"87","author":"Sharain","year":"2019","journal-title":"Hum Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001541","article-title":"Morphologic and immunohistochemical characteristics of fluorescent In situ hybridization ConfirmedTFE3-gene fusion associated renal cell carcinoma a single institutional cohort","volume":"44","author":"Akgul","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211020802","article-title":"Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report","volume":"28","author":"Paksoy","year":"2022","journal-title":"J Oncol Pharm Practice"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.204","article-title":"Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: Morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement","volume":"30","author":"Q-y","year":"2017","journal-title":"Modern Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41598-020-73309-4","article-title":"The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000835","article-title":"RBM10-TFE3 renal cell carcinoma a potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH","volume":"41","author":"Argani","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.12.018","article-title":"Does the fuhrman or world health Organization\/International society of urological pathology grading system apply to the Xp11.2 translocation renal cell carcinoma? A 10-year single-center study","volume":"188","author":"Liu","year":"2018","journal-title":"Am J Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001408","article-title":"Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs) expanding the genomic spectrum","volume":"44","author":"Xia","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0283-z","article-title":"Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: Morphology, immunohistochemistry, and FISH analysis","volume":"32","author":"Yang","year":"2019","journal-title":"Modern Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200306000-00005","article-title":"Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions - a sensitive and specific immunohistochemical assay","volume":"27","author":"Argani","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2016.07.004","article-title":"TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation","volume":"212","author":"Thorner","year":"2016","journal-title":"Pathol Res Practice"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.200","article-title":"Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase b mutation","volume":"30","author":"Calio","year":"2017","journal-title":"Modern Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.169","article-title":"Molecular heterogeneity of TFE3 activation in renal cell carcinomas","volume":"25","author":"Macher-Goeppinger","year":"2012","journal-title":"Mod Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31828a69ae","article-title":"Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service","volume":"37","author":"Green","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.208","article-title":"Clinical heterogeneity of Xp11 transiocation renal cell carcinoma: Impact of fusion subtype, age, and stage","volume":"27","author":"Ellis","year":"2014","journal-title":"Modern Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.092","article-title":"Transcription factor E3 and transcription factor EB renal cell carcinomas: Clinical features, biological behavior and prognostic factors","volume":"185","author":"Malouf","year":"2011","journal-title":"J Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181f17ac0","article-title":"A distinctive subset of PEComas harbors TFE3 gene fusions","volume":"34","author":"Argani","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000776","article-title":"Renal cell carcinoma with chromosome 6p amplification including the TFEB gene a novel mechanism of tumor pathogenesis","volume":"41","author":"Williamson","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000720","article-title":"TFEB-amplified renal cell carcinomas an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity","volume":"40","author":"Argani","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1371\/journal.pone.0015793","article-title":"Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization","volume":"5","author":"Hong","year":"2010","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-021-04235-w","article-title":"Autophagy in Xp11 translocation renal cell carcinoma: from bench to bedside","volume":"476","author":"Sun","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6930","article-title":"TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway","volume":"16","author":"Fang","year":"2017","journal-title":"Mol Med Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600134","article-title":"Combinatorial gene control involving E2F and e box family members","volume":"23","author":"Giangrande","year":"2004","journal-title":"EMBO J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag2553","article-title":"Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth","volume":"356","author":"Di Malta","year":"2017","journal-title":"Science"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1017425\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T04:40:19Z","timestamp":1665031219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1017425\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":38,"alternative-id":["10.3389\/fonc.2022.1017425"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1017425","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"1017425"}}